Overview of the clinical features of cefixime by Adam, Dieter
Chemotherapy 1998;44(suppl 1):1–5
Overview of the Clinical Features of
Cefixime
Dieter Adam
Children’s Hospital, University of
Munich, Munich, Germany
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
Key Words
Cefixime
Bacterial infection
3rd gen. cephalosporin
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
Abstract
Third-generation cephalosporins in oral formulations have
become an increasingly important first-line choice against
common bacterial infections. Cefixime is one such agent,
which possesses excellent efficacy against a broad spectrum of
pathogens, including Haemophilus influenzae, Streptococcus
pneumoniae and Moraxella catarrhalis. Clinical success rates
are similar to cefaclor, clarithromycin, and other cephalospo-
rins. Importantly, cefixime also possesses excellent activity
against beta-lactamase-producing strains. The pharmacody-
namic features of the drug include a half-life of 3–4 h and a
Cmax of 4.4 Ìg/ml, well above the MIC90 for susceptible patho-
gens, permitting once-daily dosing. In this brief overview, the
bacteriological and clinical efficacy of cefixime is discussed, as
well as its indications.
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Introduction
Cefixime is an oral 3rd gen. cephalospo-
rin, which has become increasingly well
known throughout the world. Many physi-
cians have been using it daily in the treat-
ment of bacterial infections in children as
well as adults. In light of the increased failure
rates noted with conventional antibiotics
against common infections, increased aware-
ness of regional variations in antibiotic sus-
ceptibility, and the increased use of cefixime
in the outpatient setting, it is appropriate to
present an overview of our current under-
standing of cefixime based on bacteriological
and clinical studies.
In the last few years there have been
changes in the pattern of resistance develop-
ment in some countries, but also stabilization
of resistance development, for example Strep-
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Table 1. Comparison of MIC90 for cefixime and other antibiotics against common infectious disease patho-
gens
Agent H. influenzae
ß (–) ß (+)
S. pneumoniae
Pen S Pen R
M. catarrhalis
ß (–) ß (+)
S. pyogenes
Cefaclor
Cefuroxime
Cefprozil
Amoxicillin clavulanate
Clarithromycin
Azithromycin
^0.06
8.0
2.0
8.0
1.0
16.0
2.0
^0.06
68
2.0
32
2.0
16
2.0
0.25
0.5
^0.05
^0.05
^0.12
2.0
^0.25
18.0
18.0
16
16
4.0
2.0
132
^0.12
1.0
1.0
1.0
^0.25
^0.5
^0.25
0.5
4.0
4.0
8.0
0.5
^0.05
^0.05
^0.12
^0.12
^0.05
^0.05
^0.12
^0.25
^0.23
Pen S: penicillin MIC ^ 0.06 mg/l; Pen R: penicillin MIC 62.0 mg/l (100 strains in each category).
tococcus pneumoniae, in other countries. The
overall incidence of Haemophilus influen-
zae with beta-lactamase production has in-
creased. In North America, the incidence has
increased from 16.9 to 45% from 1985 to
1994. In contrast, in Germany the rate is cur-
rently less than 5% while it reaches up to 60%
in other countries. Proper strategies for the
management of antibiotic usage must there-
fore be according to the country in which the
substance is used.
Update of the Microbiological
Situation of Cefixime
Cefixime is active against beta-lactamase-
positive H. influenzae, beta-lactamase-posi-
tive Moraxella catarrhalis and penicillin-sen-
sitive S. pneumoniae, although not against
penicillin-resistant S. pneumoniae. In addi-
tion to its broad-spectrum activity, the phar-
macokinetic profile of cefixime makes it an
ideal preparation for a number of infections.
Oral absorption is 40–50%, and excretion is
about 16–26% in urine and 10% in bile.
When considering serum concentration com-
pared with the MIC90 values of common
pathogens, most strains are found to be cov-
ered with a normal dose of 400 mg (table 1)
[1]. Peak serum concentration is reached after
4 h, with a Cmax of 4.4 Ìg/ml and a half-life of
3–4 h. Taken together, this makes it possible
to administer cefixime once daily. In addi-
tion, there are strong correlations between
concentrations of cefixime in specific tissues
and the sites where infection occurs. For ex-
ample, cefixime levels are high in tonsil, max-
illary sinus, sputum, bronchial mucosa, mid-
dle ear fluid, bile, gall bladder, urine and
inflamed tissues. The substance penetrates
well compared to all other beta-lactams, and
is similar to other cephalosporins and peni-
cillins. Macrolides and quinolones, however,
still have superior penetration characteris-
tics. When considering the pharmacokinetics
of other oral cephalosporins, a once-daily dose
of 400 mg cefixime provides steadier plasma
levels over a longer period of time. Cefurox-
ime 500 mg, cefprozil 500 mg, cefpodoxime
400 mg, and ceftibuten 400 mg have half-lives
of 1.3, 1.3, 2.5 and 2.0 h, respectively, in com-
parison to 3.5 h for cefixime.
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Fig. 1. Major bacterial pathogens responsible for infection.
Clinical Experience with Cefixime
Cefixime covers several bacterial infec-
tions that are commonly encountered by the
physician in daily practice. The indications
for cefixime are bronchitis, acute exacerba-
tions of chronic bronchitis, tonsillitis, pharyn-
gitis, sinusitis, otitis media, gonorrhea and
urinary tract infections. For all indications in
adults the dosage is fixed at 400 mg/day, with
1 or 2 divided doses possible. In pediatrics the
dose is also fixed at 8 mg/kg/day, in 1 or 2
divided doses for all indications. Figure 1 lists
the bacterial pathogens most commonly asso-
ciated with infection in various sites of the
body. Most bacteria that are responsible for
infection, excluding mycoplasma or chlamy-
dia, which are the domain of the macrolides,
can be reached by third-generation cephalo-
sporins. This includes cefixime, which is ab-
solutely stable to beta- lactamases, and which
is very active against H. influenzae. In daily
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practice, one of the most common presenta-
tions is lower respiratory tract infection. A
double-blind, randomized study has demon-
strated equivalent efficacy of cefixime 400 mg
once daily (n = 110) to clarithromycin 500 mg
twice daily (n = 103), with cure or improve-
ment rates of 86 and 88%, respectively [2].
New Developments
One recent development in the treatment
of infection is intravenous switch therapy,
brought about both by the recent availability
of oral cephalosporins with excellent activity
and by the pressure placed on hospitals to
reduce costs. The concept of switch therapy is
as follows: upon hospital admission for a seri-
ous infection, the physician prescribes em-
piric therapy consisting of an intravenous
third-generation cephalosporin, then after a
few days switches to an oral third generation
cephalosporin, following which the patient is
discharged. Cefixime has proved itself a po-
tent switch-down agent for a number of indi-
cations.
In addition, cefixime has proved itself a
potent agent in short-course therapy. In one of
our studies, treatment of patients with group
A beta-hemolytic streptococcal (GABHS)
pharyngitis was compared. Cefixime 8 mg/kg/
day qd for 5 days (n = 65) versus penicillin V
200,000 IU/kg tid for 10 days (69%) resulted
in clinical cure rates of 86.7 and 90.8%,
respectively [3–5]. These were administered
under study conditions, which indicates that
the situation was controlled and that the peni-
cillin was given for the full 10 days. Normally,
however, patients tend to stop treatment after
5 or 6 days with penicillin V, reducing the
actual efficacy rate. A recent study of 5,500
GABHS pharyngitis patients in Germany, in-
dicated no difference between 5-day treat-
ment with a cephalosporin or a macrolide and
a standard 10-day course of penicillin V. In
the future, it may be possible to recommend
5-day cefixime treatment of GABHS pharyn-
gitis, following approval from the regulatory
authorities. We are therefore now planning a
study of 5-day penicillin treatment. If relapse
or failure occurs more frequently with the
penicillin V treatment, then it will support the
use of one of the third-generation cephalospo-
rins, such as cefixime, or macrolides for 5
days. It is of interest to note that one 4-day
study in GABHS pharyngitis patients showed
resolution with cefixime at 2.2 days and with
penicillin V at 2.7 days, although it is still rec-
ommended to use 5-day treatment. Addition-
al studies are required to clarify optimum
treatment regimens.
Safety Profile of Cefixime
As with other cephalosporins, the most sig-
nificant adverse events with cefixime relate to
the gastrointestinal tract and the skin. There
are no specific problems associated with cefix-
ime that are not reported for other cephalo-
sporins. A recent postmarketing survey in-
volving over 47,000 patients in Germany, the
US and Canada has shown side effect inci-
dences of between 1.6 and 11.5%, which is
also comparable to those reported for other
cephalosporins. In a US study of safety pro-
file, 5.5% children and 7.7% adults had to dis-
continue therapy. In France and Germany the
rates are much lower (0.7 and 0.9%, respec-
tively), which likely reflects the differences
from country to country in interpreting what
constitutes a side effect and event. Patient
compliance with cefixime is expected to be
superior to that observed with other prepara-
tions that require multiple daily dosing, as
supported by the finding that in general once-
daily dosage results in the best compliance, at
about 85%, while it decreases to 60% with
Overview of the Clinical Features of
Cefixime
Chemotherapy 1998;44(suppl 1):1–5 5
3-times daily dosing. If a substance has to be
given 3 times daily, it goes down to 60%, with
the mid-day dose in most cases not being giv-
en in children, for example, resulting in insuf-
ficient tissue concentrations throughout the
day. A further advantage of cefixime is the
well-tolerated liquid suspension available for
pediatric patients, which has a favorable
taste.
In summary, the clinical features of cefix-
ime make it an important first-line choice for
physicians against a variety of common infec-
tions encountered in daily practice. These in-
clude its efficacy against a wide range of
pathogens, well-proven safety, a long half-life
allowing once-daily dosing, fixed dosage for
all indications, excellent beta- lactamase sta-
bility, and good tasting pediatric suspension.
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